CureMatch at ASCO18 To Discuss Benefits of Precision Medicine
CureMatch’s CEO Stephane Richard (@StephR1chard) is attending the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. #ASCO18!
Connect with Steph
With over 32,000 oncology professionals in attendance, we recommend you connect with Steph directly or on social media to set up a meeting.
This year’s theme is “Delivering Discoveries: Expanding the Reach of Precision Medicine” and by now everyone is realizing that Precision Medicine is not just a buzzword, but technology revolutionizing cancer care. This is quite evident here at CureMatch, founded in 2015 to arm doctors with intelligent genomic analysis to fight this disease one patient at a time.
Expanding the Reach
CureMatch is in position to bridge the gap toward this more precise and personalized approach to oncology care. The reduction in lab costs of genomic analysis has provided access to technologies and insights that only the elite could afford just 5 years ago. CureMatch offers a path of improved analysis for every oncologist who would like to find drug treatments matched to their patients’ cancer biomarkers.
CureMatch wants to find you too. We’re on a mission to meet oncologists, care clinics, NGS labs, as well as other collaborators and partners.
#ASCO18 will be held during Jun 01 – 05, 2018 at McCormick Place in Chicago. This is the Annual Meeting which brings together oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. The ASCO Annual Meeting offers informative educational and scientific sessions that highlight the latest in cancer care treatments. The Sessions at a Glance Grid provides a detailed look at all Clinical Science Symposia, Education Sessions, Extended Education Sessions, Meet the Professor Sessions, and Clinical Problems in Oncology Sessions organized by primary track, as well as by date and time.
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations in cost-effective PreciGENE reports. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com